Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2024; 15(5): 867-875
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.867
Role of angiotensin receptor-neprilysin inhibitor in diabetic complications
Ying Liu, Cun-Yu Lu, Yi Zheng, Yu-Min Zhang, Ling-Ling Qian, Ku-Lin Li, Gary Tse, Ru-Xing Wang, Tong Liu
Ying Liu, Yi Zheng, Gary Tse, Tong Liu, Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
Cun-Yu Lu, Department of Cardiology, Xuzhou No. 1 Peoples Hospital, Xuzhou 221005, Jiangsu Province, China
Yu-Min Zhang, Department of Cardiology, Wuxi 9th People’s Hospital Affiliated to Soochow University, Wuxi 214062, Jiangsu Province, China
Ling-Ling Qian, Ku-Lin Li, Ru-Xing Wang, Department of Cardiology, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi 214023, Jiangsu Province, China
Gary Tse, School of Nursing and Health Studies, Metropolitan University, Hong Kong 999077, China
Gary Tse, Kent and Medway Medical School, Kent CT2 7NT, Canterbury, United Kingdom
Co-first authors: Ying Liu and Cun-Yu Lu.
Author contributions: Liu Y and Qian LL contributed to the conceptualization of this review; Zhang YM and Li KL performed the literature search; Liu Y, Lu CY, and Zheng Y drafted the work and finally; Tse G, Wang RX, and Liu T critically revised the work; and all authors have read and approved the final manuscript; Wang RX and Liu T contributed equally to this paper.
Supported by Tianjin Key Medical Discipline (Specialty) Construction Project, No. TJYXZDXK-029A; and the National Natural Science Foundation of China, No. 82370342.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tong Liu, PhD, Professor, Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin 300211, China. liutongdoc@126.com
Received: October 8, 2023
Peer-review started: October 8, 2023
First decision: December 18, 2023
Revised: December 31, 2023
Accepted: March 25, 2024
Article in press: March 25, 2024
Published online: May 15, 2024
Processing time: 215 Days and 10.1 Hours
Core Tip

Core Tip: Diabetes mellitus is a prevalent disorder with multi-system manifestations, causing a significant burden in terms of disability and deaths globally. Angiotensin receptor-neprilysin inhibitor (ARNI) belongs to a class of medications for treating heart failure, with the benefits of reducing hospitalization rates and mortality. This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications, discussing possible physiological and molecular mechanisms, with insights for future applications.